Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q8NE79: Variant p.Ser201Phe

Blood vessel epicardial substance
Gene: BVES
Feedback?
Variant information Variant position: help 201 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Phenylalanine (F) at position 201 (S201F, p.Ser201Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LGMDR25; reduces membrane localization of BVES and POPDC2; decreases by 50% affinity for cAMP; disrupts enhancement of KCKN2 surface expression; increases KCKN2 outward currents; no effect on total protein levels. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 201 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 360 The length of the canonical sequence.
Location on the sequence: help MKVSYRGHFLHNIYPCAFID S PEFRSTQMHKGEKFQVTIIA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         MKVSYRGHFLHNIYPCAFIDSPEFRSTQMHKGEKFQVTIIA

Mouse                         MKVSYRGHFLHNIYPCAFIDSPEFRSTQMHKGEKFQVTIVA

Rat                           MKVSYRGHFLHNIYPCAFIDSPEFRSTQMHKGEKFQVTIVA

Pig                           MKVSYRGHFLHNIYPCAFIDSPEFRSTQMHKGEKFQVTIIA

Chicken                       MKVSYRGHFLHNIYPCAFIDSPEFRSTQMNRGEKFQVTIIA

Xenopus tropicalis            MKVSYRGHFLHAISPNAYIDSPEFRSTEMNRGETFQVTITA

Zebrafish                     MKVSYRGHFLHNIYTNAFIDSPEFRSTQMNRGERFQVTIAA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 360 Blood vessel epicardial substance
Topological domain 114 – 360 Cytoplasmic



Literature citations
POPDC1S201F causes muscular dystrophy and arrhythmia by affecting protein trafficking.
Schindler R.F.; Scotton C.; Zhang J.; Passarelli C.; Ortiz-Bonnin B.; Simrick S.; Schwerte T.; Poon K.L.; Fang M.; Rinne S.; Froese A.; Nikolaev V.O.; Grunert C.; Mueller T.; Tasca G.; Sarathchandra P.; Drago F.; Dallapiccola B.; Rapezzi C.; Arbustini E.; Di Raimo F.R.; Neri M.; Selvatici R.; Gualandi F.; Fattori F.; Pietrangelo A.; Li W.; Jiang H.; Xu X.; Bertini E.; Decher N.; Wang J.; Brand T.; Ferlini A.;
J. Clin. Invest. 126:239-253(2016)
Cited for: INVOLVEMENT IN LGMDR25; VARIANT LGMDR25 PHE-201; FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; INTERACTION WITH KCNK2; CAMP-BINDING;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.